“Patients with Lennox-Gastaut syndrome, a rare, severe form of epileptic encephalopathy, are frequently treatment resistant to available medications.
No controlled studies have investigated the use of cannabidiol for patients with seizures associated with Lennox-Gastaut syndrome.
We therefore assessed the efficacy and safety of cannabidiol as an add-on anticonvulsant therapy in this population of patients.
Add-on cannabidiol is efficacious for the treatment of patients with drop seizures associated with Lennox-Gastaut syndrome and is generally well tolerated.“
“This study is registered with ClinicalTrials.gov, number NCT02224690.”